It is very difficult to comment on the rational of use of albumin in clinical practice. Interpretation of the literature is made difficult by variations in patients, targets, additive therapy, and other factors. When selecting a specific fluid, consideration should be focussed on organ function, endothelial inflammation, or tissue perfusion. A major challenge is to decide which kind of therapeutic strategy is associated with the greatest benefit and fewest disadvantages for the critically ill patient. In the absence of supportive data in literature, albumin containing solutions are still widely used for volume replacement in these patients. Interestingly, despite several advices not to use albumin, the plasma products industry has launched a 1.4 million British Pound international program to promote albumin! There are no convincing data justifying administration of albumin either for treating hypovolemia or for correcting hypoalbuminemia.
Mendeley saves you time finding and organizing research
There are no full text links
Choose a citation style from the tabs below